Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

Recruiting Observational Study
Coronary Artery Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 70
Sex
Any
Study type
Observational
Participants needed
748 (estimated)
Sponsor
Baker Heart and Diabetes Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer). Exclusion Criteria: * Unable to provide written informed consent to participate in this st…
Contacts

Tom Marwick, MBBS,PhD,MPH

+61 3 8532 1550

tom.marwick@baker.edu.au

CONTACT

Lisa Riddell

+61 3 8532 1550

lisa.riddell@baker.edu.au

CONTACT